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A B S T R A C T
Purpose
For over 30 years, the place of consolidation high-dose chemotherapy in Ewing sarcoma (ES)
has been controversial. A randomized study was conducted to determine whether consolida-
tion high-dose chemotherapy improved survival in patients with localized ES at high risk for relapse.
Methods
Randomization between busulfan and melphalan (BuMel) or standard chemotherapy (vincristine,
dactinomycin, and ifosfamide [VAI], seven courses) was offered to patients if they were younger
than 50 years of age with poor histologic response ($ 10% viable cells) after receiving vincristine,
ifosfamide, doxorubicin, and etoposide (six courses); or had a tumor volume at diagnosis$ 200mL if
unresected, or initially resected, or resected after radiotherapy. A 15% improvement in 3-year event-
free survival (EFS) was sought (hazard ratio [HR], 0.60).
Results
Between 2000 and 2015, 240 patients classiﬁed as high risk (median age, 17.1 years) were randomly
assigned to VAI (n = 118) or BuMel (n = 122). Seventy-eight percent entered the trial because of poor
histologic response after chemotherapy alone. Median follow-up was 7.8 years. In an intent-to-treat
analysis, the risk of eventwas signiﬁcantly decreased by BuMel comparedwith VAI: HR, 0.64 (95%CI,
0.43 to 0.95; P = .026); 3- and 8-year EFS were, respectively, 69.0% (95%CI, 60.2% to 76.6%) versus
56.7% (95%CI, 47.6% to 65.4%) and 60.7% (95%CI, 51.1% to 69.6%) versus 47.1% (95%CI, 37.7%
to 56.8%). Overall survival (OS) also favored BuMel: HR, 0.63 (95% CI, 0.41 to 0.95; P = .028); 3- and
8-year OS were, respectively, 78.0% (95% CI, 69.6% to 84.5%) versus 72.2% (95% CI, 63.3% to
79.6%) and 64.5% (95%CI, 54.4% to 73.5%) versus 55.6% (95%CI, 45.8% to 65.1%). Results were
consistent in the sensitivity analysis. Two patients died as a result of BuMel-related toxicity, one after
standard chemotherapy. Signiﬁcantly more BuMel patients experienced severe acute toxicities from
this course of chemotherapy compared with multiple VAI courses.
Conclusion
BuMel improved EFS and OS when given after vincristine, ifosfamide, doxorubicin, and etoposide
induction in localized ES with predeﬁned high-risk factors. For this group of patients, BuMel may be
an important addition to the standard of care.
J Clin Oncol 36. © 2018 by American Society of Clinical Oncology
INTRODUCTION
Treatment advances in Ewing sarcoma (ES) have
largely resulted from amultidisciplinary approach
to clinical trials conducted by national and in-
ternational cooperative groups. Over the years,
these trials have answered key chemotherapy
questions and better deﬁned risk groups, allowing
tailored treatment strategies. Prolonged disease-free
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survival is achieved in the majority of patients with localized ES after
treatment with multiagent chemotherapy and primary tumor con-
trol.1-4 Larger initial tumor volume is a well-deﬁned adverse prog-
nostic factor,5-8 the predictive power of which is over-ridden by the
extent of histologically determined chemotherapy-induced necrosis
assessed in resected primary tumors.4,8-11 These observations can be
used to deﬁne subgroups of patients with localized ES in whom
treatment interventions to improve survival may be examined.
The rationale for high-dose therapy (HDT) in ES was de-
veloped to exploit an alkylating agent dose-response relationship.
Several single-arm studies have indicated high-dose chemo-
therapy efﬁcacy using historical controls in newly diagnosed
metastatic or recurrent ES, using various drugs or combinations
with or without total-body irradiation.12-18 Two national non-
randomized studies evaluated the role of busulfan-melphalan
(BuMel) in patients with poor histologic response and suggested its
potential beneﬁt compared with historical controls treated with
conventional chemotherapy.19,20 Because these encouraging results
were based on uncontrolled comparisons, a randomized comparison
of high-dose chemotherapy against standard chemotherapy was
therefore incorporated in two multinational controlled trials, Euro-
E.W.I.N.G.99 and EWING-2008. In the selected high-risk pop-
ulation, termed R2Loc, the primary objective was to evaluate
whether HDT using BuMel improved event-free survival (EFS)
compared with standard chemotherapy (vincristine, dactinomycin,
ifosfamide [VAI]).
METHODS
Study Design
The R2Loc trial was an international, randomized, superiority trial
comparing consolidation treatment with BuMel or seven VAI courses in
a two-parallel-group design. The R2Loc randomized trial was a com-
ponent of the Euro-E.W.I.N.G.99 study (ClinicalTrials.gov identiﬁer:
NCT00020566) recruiting all patients with ES at diagnosis, enrolled by
four cooperative groups: European Organization for Research and
Treatment of Cancer (EORTC), Gesellschaft fu¨r Pa¨diatrische Onkologie
und Ha¨matologie (GPOH), French Society of Pediatric Oncology and
French Sarcoma Group, and the UK Children’s Cancer and Leukaemia
Group.1,21,22 From May 2010, patients from GPOH were recruited in the
same R2Loc randomized trial conducted through the EWING-2008
study (ClinicalTrials.gov identiﬁer: NCT00987636).
Patients
Eligibility requirements were age younger than 50 years; enrollment at
diagnosis either in Euro-E.W.I.N.G.99 or EWING-2008 studies for newly
diagnosed biopsy-proven ES; localized disease classiﬁed as high risk because
of poor histologic response to induction chemotherapy (residual viable
cells$ 10%) for patients undergoing surgery after induction chemotherapy
alone or because of large tumor volume at diagnosis ($ 200 mL) in
unresected or initially resected tumors or resected tumors with preoperative
irradiation, but patients with a small unresected tumor were also eligible in
case of poor clinical response to induction chemotherapy (, 50% radiologic
reduction in soft tissue disease component); and no medical contraindi-
cation to treatment. After amendment, because of busulfan-related radio-
sensitivity,23 patients expected to receive radiotherapy. 30 Gy to the spinal
cord (Amendment July 2004) or . 45 Gy to large intestinal volume
(Amendment November 2008) were no longer eligible. Written informed
consent was obtained from all patients and/or their parents/guardians before
enrollment.
Treatments
Induction chemotherapy consisted of six chemotherapy courses
combining vincristine, ifosfamide, doxorubicin, and etoposide (VIDE).21,24
After one VAI course, allocated consolidation treatment was either seven VAI
courses (VAI arm) or one course of high-dose BuMel chemotherapy with
autologous stem-cell transplant (BuMel arm). Treatment schedule and
chemotherapy details are in the Data Supplement.
Local therapy was tailored to patient and tumor characteristics, and
included surgery with complete surgical removal wherever feasible, ra-
diotherapy, or a combination of both (Data Supplement). Stem-cell
harvest was undertaken according to local practice after VIDE course 2.
Randomization
Random assignment was performed after six VIDE courses plus one
VAI consolidation course, after surgery and assessment of histologic re-
sponse when applicable. Randomization was balanced and stratiﬁed
according to cooperative group, sex, age (younger than 25 years), and
local treatment (resection after chemotherapy alone with or without
postoperative radiotherapy v initial surgery v resection after chemo-
therapy and radiotherapy v radiotherapy only). Centralized randomi-
zation software was used in all data centers, ensuring the concealment of
the next patient allocation. The GPOH data center used permuted blocks
of four. In the other data centers, randomization was also balanced by the
treating center using dynamic allocation of treatment (minimization
with a random factor set at 0.8).
End Points and Assessments
The primary end point was EFS, deﬁned as the time from ran-
domization to the date of the ﬁrst failure assessed by the investigator
(progression, relapse, second malignancy, or death, whatever the cause).
Follow-up was planned every 3 months during the ﬁrst 3 years, every
6 months during years 4 and 5, then yearly, regardless of treatment
compliance. Overall survival (OS) since randomization was a secondary
efﬁcacy end point, considering all deaths, whatever the cause.
Central imaging review of tumor volume and response, and path-
ologic review were not undertaken. Compliance with treatment and
toxicity were monitored. All chemotherapy doses were recorded, as well as
the reasons for dose reduction or delay. Acute toxicity related to che-
motherapy was assessed after each course, using a list of 22 selected items
from the National Cancer Institute Common Toxicity Criteria version 2.0
and Bearman’s criteria for sinusoidal obstruction syndrome.25 Other
adverse reactions were speciﬁed. A modiﬁed list was used to evaluate
toxicity after radiotherapy, using Radiation Therapy Oncology Group
classiﬁcation for 17 toxicities.26 For each toxicity type, the maximum grade
observed over the whole maintenance treatment was computed, including
radiotherapy to the primary site. Grade 4 hematologic toxicities and grade
3 or higher of all nonhematologic toxicities were considered severe.
Statistical Analysis
The study was designed to ensure 80% power for a 40% reduction in
the risk of an event in the BuMel arm compared with the VAI arm (expected
3-year EFS, 70% v 55%; hazard ratio [HR], 0.60) with a two-sided log-rank
test a of .05. The initial target sample size was 328 patients (124 events).27
With support from the independent data monitoring committee, re-
cruitment was stopped before reaching this target because of low accrual.
This is the ﬁnal analysis, on the basis of data as of July 2016.
Preplanned efﬁcacy stopping rules were deﬁned using the a spending
function approach with O’Brien-Fleming boundaries.28,29 These analyses
were only disclosed to the independent monitoring committee. Survival
rates (EFS and OS) were estimated using the Kaplan-Meier method with
Rothman’s 95% CIs. Median follow-up was estimated using the reverse
Kaplan-Meier method. The HR of event (EFS) and the HR of death (OS)
were estimated in Cox models. The point estimate of the HR of event, its
CI, and the P value were corrected for the four previous interim analyses
2 © 2018 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
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using the inverse normal method.31 The primary efﬁcacy analysis was
performed according to the patients’ randomly assigned treatments (ie, by
intention-to-treat population). Post hoc sensitivity analyses were performed,
(1) adjusting for age (in four categories:, 12, 12 to 18, 18 to 25,. 25 years)
and (2) excluding patients with a major treatment modiﬁcation (as-treated;
Data Supplement). The heterogeneity of treatment effect (BuMel v VAI)
on EFS according to stratiﬁcation variables and tumor volume, tumor site,
and histologic response (post hoc exploratory analysis) were evaluated in
multivariable models, including interaction terms, and illustrated in a forest
plot. Because the EFS is a composite end point, a competing risk approach
was also used to estimate the effect of treatment on the risk of metastases
using subdistribution HRs considered competing events: local progression/
relapse without concomitant metastases, secondary malignancy, and death
without prior metastases (post hoc analysis).32,33
Safety analyses were performed on the safety set, excluding patients
who did not receive the assigned treatment (as-treated population). For
Assigned to Bu-Mel (n = 122)
Eligible for R2loc trial (n = 114)
(n = 8)Not eligible for R2loc trial
Patients potentially eligible not included (n = 365)
(n = 144)
(n = 77)
(n = 123)
(n = 21)
Patient/parent refusal
Physician refusal
Miscellaneous reason
Unknown reason yet
Patients with localized high-risk disease
enrolled in the Euro-E.W.I.N.G.99-EWING-2008 studies
(N = 753) 
Patients enrolled in R2Loc randomized trial
(n = 240)
Patients potentially eligible
(n = 605)
Lost-to-follow-up in the first 3 years
(n = 1)
Lost-to-follow-up in the first 3 years
(n = 1)
Received assigned intervention (n = 116)
(n = 1)Received Bu-Mel
(n = 1)With missing information
In the intention-to-treat analysis    (n = 118)
In the as-treated data set      (n = 116)
High-risk patients screened for eligibility
(n = 716)
Patients not meeting eligibility criteria
(n = 111)
Progressions or deaths
     before randomization timepoint
(n = 37)
Assigned to VAI (n = 118)
Eligible for R2loc trial (n = 114)
(n = 4)Not eligible for R2loc trial
Received assigned intervention (n = 93)
(n = 21)
(n = 6)
(n = 2)
Did not receive Bu-Mel HDT
Received another HDT
With missing information
In the intention-to-treat analysis
In the as-treated data set    (n = 93)
(n = 122)
Fig 1. Trial proﬁle. A total of 111 patients
with disease classiﬁed as localized high-risk
disease assessed for eligibility did not meet
eligibility criteria: insufﬁcient diagnosis criteria
or diagnosis rejected (n = 14); persisting tox-
icity related to previous treatment and/or
contraindication to planned treatment (n = 78),
including contraindication to busulfan and
melphalan (BuMel) because of planned ra-
diotherapy to an axial site (n = 36); early ra-
diotherapy (n = 13); psychological problems
(n = 6); 123 patients meeting eligibility criteria
were not enrolled because of other reasons.
HDT, high dose therapy; R2Loc, selected high-
risk population; VAI, vincristine, dactinomycin,
and ifosfamide.
jco.org © 2018 by American Society of Clinical Oncology 3
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each toxicity category, the relative risk of having experienced a severe
toxicity in BuMel versus VAI was estimated.
Estimates are provided with 95% CIs. All tests are two sided. The
analyses were performed using SAS 9.3 software (SAS Institute, Cary, NC).
Study Oversight
Study protocols were approved by an independent ethics committee
and the appropriate institutional review boards. The studies were con-
ducted in accordance with the ethical principles of the Declaration of
Helsinki and with Good Clinical Practice guidelines. The trial was designed
jointly by the senior academic authors from the participating cooperative
groups. The protocols are available online. Data were analyzed by the
biostatisticians at Institut Gustave Roussy and reviewed by the statisticians’
board. The ﬁrst draft of this article was written byM.C.L.D., O.O., and J.W.
All authors contributed to subsequent drafts and made the decision to
submit the manuscript for publication. None of the funders had a role in
study design, collection, analysis, or interpretation of data.
RESULTS
Patients
Between February 2000 and December 2015, 716 patients
with a localized tumor fulﬁlling the predeﬁned high-risk criteria,
enrolled in 131 centers from 13 countries, were assessed for
eligibility. Among them, 111 did not meet eligibility criteria
(details in the legend of Fig 1). Of 605 eligible patients, 221 were
not enrolled because of patient/parent (n = 144) or physician (n =
77) refusal, 123 for other reasons, and 21 for whom the reason
was unknown; 240 patients were included in the randomized
trial: 118 assigned to VAI and 122 assigned to BuMel (Fig 1). The
median age was 17.1 years (range, 11 months to 44.7 years). The
baseline characteristics were well balanced between the two
groups (Table 1), although over the course of the study, some
changes were notable, with a greater proportion with less fa-
vorable histologic response represented (Data Supplement).
Overall, 188 of the 240 patients (78%) entered the trial because of
poor histologic response after chemotherapy alone. Median follow-
up was 7.8 years and was not signiﬁcantly different between treat-
ment groups (Data Supplement). Among the 240 enrolled patients,
four patients in the VAI arm and eight patients in the BuMel arm
were not eligible (Data Supplement).
One patient allocated to VAI received BuMel on his request. In
the BuMel arm, 21 patients did not receive any HDT because of
patient refusal (n = 11), medical reason (n = 7), physician decision
(n = 2), or failure to collect peripheral stem cells (n = 1); six patients
received HDTother than BuMel because of physician decision in ﬁve
Table 1. Patient and Tumor Baseline Characteristics
Characteristics VAI (n = 118) BuMel (n = 122) Total (n = 240)
Gender, No. (%)
Male 73 (62) 75 (61) 148 (61)
Female 45 (38) 47 (39) 92 (38)
Median age, years (range) 17.1 (0.9-43) 17.4 (2.5-45) 17.1 (0.9-45)
Recruiting group , No. (%)
EORTC 8 (7) 9 (7) 17 (7)
UKCCLG 20 (17) 21 (17) 41 (17)
SFCE/GSF/Unicancer 37 (31) 37 (30.5) 74 (31)
GPOH 42 (36) 42 (34.5) 84 (35)
GPOH-Ewing2008 11 (9) 13 (11) 24 (10)
Follow-up
Median duration, years (range) 8.7 (0.1-13.4) 7.4 (0.08-13.9) 7.8 (0.08-13.9)
Lost to follow-up in the ﬁrst 3 years, No. (%) 1 (1) 1 (1) 2 (2)
Primary tumor site, No. (%)
Axis 66 (56) 70 (57) 136 (57)
Limb 52 (44) 52(43) 104 (43)
Tumor volume (1 MD), No. (%)
, 200 mL 57 (48) 59 (48) 116 (48)
$ 200 mL 60 (52) 63 (52) 123 (52)
Classiﬁcation high-risk group/local treatment, No. (%) 118 122 240
Poor histologic response after chemotherapy alone 93 (79) 95 (78) 188 (78)
10%-29% viable cells 39 (33) 42 (34) 81 (34)
$ 30% viable cells 52 (44) 51 (42) 103 (43)
Poor histologic response, NOS 2 (2) 2 (2) 4 (2)
Large tumor, histologic response not applicable 21 (18) 19 (16) 40 (17)
Preoperative radiotherapy 1 (1) 2 (2) 3 (1)
Initial surgery 6 (5) 6 (5) 12 (5)
Exclusive radiotherapy 14 (12) 10 (8) 24 (10)
Other 0 1 (1) 1 (, 1)
Other 0 (0) 2 (2) 2 (1)
Small tumor with exclusive radiotherapy, but poor clinical
response
0 (0) 2 (2) 2 (1)
Nonhigh-risk group* 4 (3) 6 (5) 10 (4)
Abbreviations: BuMel, busulfan and melphalan; EORTC, European Organization for Research and Treatment of Cancer; GPOH, Gesellschaft fu¨r Pa¨diatrische Onkologie
und Ha¨matologie; GSF, French Sarcoma Group; MD, missing data; NOS, not otherwise speciﬁed; SFCE, French Society of Pediatric Oncology; UKCCLG, Children’s
Cancer and Leukaemia Group; VAI, vincristine, dactinomycin, and ifosfamide.
*As detailed in the Data Supplement, 10 patients were enrolled in the randomized trial, although they were ineligible.
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No. Events / No. Patients
BuMel Better VAI Better
Poor response
Age, years
Category
< 12 
12-18 
18-25
> 25
Recruiting group
EORTC
UKCCLG
French group
GPOH
Tumor site
Limb
Axis
Tumor volume
< 200 ml
≥ 200 ml
High-risk group
Large tumor
Poor response, %
10-29 cells
≥ 30 cells
Overall
VAI
9/24
21/40
14/25
16/29
5/8
10/20
23/37
22/53
27/52
33/66
22/57
37/60
49/93
10/21
24/39
24/52
60/118
BuMel
8/33
11/36
10/25
16/28
4/9
8/21
16/37
17/55
16/52
29/70
19/59
26/63
37/95
7/19
14/42
23/51
45/122
0.2 5.01.0
Hazard Ratio
0.64 (0.25 to 1.67)
0.53 (0.25 to 1.10)
0.52 (0.23 to 1.17)
1.04 (0.52 to 2.08)
0.56 (0.15 to 2.09)
0.69 (0.27 to 1.76)
0.61 (0.32 to 1.16)
0.67 (0.35 to 1.26)
0.49 (0.26 to 0.91)
0.79 (0.48 to 1.31)
0.77 (0.42 to 1.43)
0.55 (0.33 to 0.92)
0.65 (0.42 to 1.00)
0.74 (0.28 to 1.96)
0.42 (0.22 to 0.82)
0.97 (0.55 to 1.73)
0.64 (0.43 to 0.94)
.80
.99
.23
.41
.51
.06
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Fig 2. (A and B) Event-free survival (EFS) and (C) overall survival. (A) Kaplan-Meier estimates of EFS by treatment group, on the intention-to-treat (ITT) population.
At the time of this analysis (cutoff date, Jan 1, 2016), 105 events were reported: 60 in the vincristine, dactinomycin, and ifosfamide (VAI) group and 45 in the busulfan
and melphalan (BuMel) group. (B) Forest plot of EFS according to subgroups. The hazard ratio of events by subgroup were estimated in a Cox proportional hazards
model, on the ITT population including all patients, except for the (1) assessment of treatment effect according to tumor volume: we excluded one patient with
missing data; (2) assessment of treatment effect by the high-risk group deﬁnition (poor response v large tumor): we excluded 10 patients who were not classiﬁed as
high risk (listed in the Data Supplement) and two patients who entered the trial for a small tumor with exclusive radiotherapy, but poor (continued on next page)
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patients and BuMel contraindication in one patient (Data Supple-
ment). These 28 patients were excluded in the as-treated analysis.
When grouped by selected factors, the proportions of patients
randomly assigned to those not randomly assigned varied (data not
shown). There were differences by study year, study group, age,
tumor volume, histologic response, and treatment with radiotherapy.
Efficacy
A total of 105 events were reported (VAI arm, 60; BuMel arm,
45): 13 local progressions or local relapses, 80 distant metastases
(including lung metastases in 51 patients), ﬁve secondary malig-
nancies, and seven deaths as ﬁrst events (Data Supplement), in-
cluding three treatment-related deaths.
EFS for all 240 randomly assigned patients was 62.9% (95%
CI, 56.6% to 68.9%) at 3 years and 54.0% (95% CI, 47.2% to
60.7%) at 8 years. The treatment effect of BuMel was estimated as
an HR of 0.64 (95% CI, 0.43 to 0.95; P = .026), corrected for the
four previous interim analyses. Three-year EFS rates for VAI and
BuMel were 56.7% (95% CI, 47.6% to 65.4%) and 69.0% (95% CI,
60.2% to 76.6%), respectively, with this improvement being
sustained at 8 years: 47.1% (95% CI, 37.7% to 56.8%) versus
60.7% (95% CI, 51.1% to 69.6%; Fig 2A; Table 2), respectively. The
treatment effect estimate seems greater in the sensitivity analysis,
when patients with protocol violations were excluded (Table 2). As
illustrated in Figure 2B, no signiﬁcant heterogeneity of the
treatment effect was observed according to cooperative group,
tumor site, tumor volume, or eligibility criteria for high-risk
classiﬁcation. However, patients with an intermediate poor re-
sponse may beneﬁt more than those with a very poor response
(10% to 29% v$ 30% viable cells; interaction test, P = .06), as well
as older patients (# 25 v. 25 years of age; P = .12). Improvement
in EFS was mostly related to a reduction in the risk of metastases
(subdistribution-HR, 0.58; 95% CI, 0.37 to 0.90; P = .02; Data
Supplement).
Beneﬁt from BuMel was also observed in OS. Ninety deaths
were reported (VAI, 53; BuMel, 37), leading to an HR of 0.63 (95%
CI, 0.41 to 0.95; P = .028). Three-year OS was 72.2% (95% CI,
63.3% to 79.6%) and 78.0% (95%CI, 69.6% to 84.5%) for VAI and
BuMel, respectively (Fig 2C), and 75.1% (95%CI, 69.2% to 80.2%)
overall. Eight-year OS was 55.6% (95% CI, 45.8% to 65.1%) versus
64.5% (95% CI, 54.4% to 73.5%).
Safety
Signiﬁcantly more BuMel patients experienced severe acute
toxicities (Fig 3), but toxicity arose from a single high-dose course
versus multiple VAI courses (Data Supplement). The effect of
BuMel on the risk of severe acute toxicity did not differ between
patients older than 25 years and younger patients (Data Supple-
ment). Three treatment-related deaths were reported in the BuMel
arm, although one was in a patient who did not receive BuMel
because of renal dysfunction. One patient with a cervical spine
primary site died as a result of myelopathy related to radiotherapy
administered after BuMel, and one patient with a chest wall
primary site died as a result of acute respiratory distress syndrome
associated with pancytopenia 5 months after receiving BuMel.
DISCUSSION
In the subgroup of patients with localized ES speciﬁcally deﬁned
for this study, treatment with BuMel conferred a signiﬁcant,
sustained, and clinically meaningful improvement (European
Society for Medical Oncology–Magnitude of Clinical Beneﬁt Scale
grade A) in EFS and OS.34 This outcome was despite the ﬁnal
analysis being conducted after recruitment of only 240 of a planned
328 patients and was sustained with prolonged follow-up. This
ﬁnding is particularly signiﬁcant, given the observation that cure
rates in this important cancer of children and young people have
improved modestly at best over recent decades and that the
expanding knowledge of the biology of ES has, to date, not resulted
in the introduction of new agents into standard care.35
Several factors deserve more detailed consideration. First, this
was a complex but pragmatic trial performed by an experienced
multinational cooperative group that encompassed a large pro-
portion of major pediatric and sarcoma-treating centers in Europe.
Despite this, recruitment fell short of the recruitment rates pro-
posed at study initiation. The study was closed before the planned
event/patient target was reached because of some investigators’
concerns that rates of participation in the study were too low to be
sustainable. Of patients within the study registration cohort, one
third of those fulﬁlling the deﬁnition of localized high-risk disease
were ultimately randomly assigned, with evidence of low ac-
ceptability of the study question to both clinicians and patients. We
acknowledge that this limits the external validity of our ﬁndings.
However the description of a screened population and the estimate
of randomization rate are missing from other studies, and sets this
intervention into a clinically meaningful context.
The use of histologic response as the main selection criterion
identiﬁes a population of patients with some degree of initial drug
resistance. In R2Loc, this is supplemented by other high-risk pa-
tients, accounting for 20% of randomly assigned patients, for whom
histologic response was not available, those with tumors . 200 mL
who had undergone primary surgery or had early radiotherapy or
exclusive radiotherapy. This subset of patients may include patients
with unidentiﬁable good response to induction chemotherapy.
Overall, the BuMel effect seemed consistent across main strata
(cooperative group, tumor site, tumor volume, or eligibility criteria
for high-risk classiﬁcation). Within the poor histologic response
spectrum, it is possible that BuMel may have less beneﬁt in those
with poor response, although, given that this was an observation
from a post hoc exploratory analysis, it is insufﬁcient evidence to be
clinical response (too small category); and (3) assessment of treatment effect according to the grading of histologic response in patients with poor response:
we focused the analysis on the 188 patients who entered the trial because of a poor histologic response and excluded four patients with poor response not otherwise
speciﬁed. French group: French Society of Pediatric Oncology/French SarcomaGroup/Unicancer. Concerning the interaction between treatment effect and age, the P value
was .12 when agewas considered in two categories using the cutoff of 25 years as deﬁned at the design stage to stratify the randomization. (C) Kaplan-Meier estimates for
overall survival by treatment group on the ITT population. EORTC, European Organization for Research and Treatment of Cancer; GPOH, Gesellschaft fu¨r Pa¨diatrische
Onkologie und Ha¨matologie; UKCCLG, UK Children’s Cancer and Leukaemia Group
(Continued).
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used alone to exclude patients from treatment with BuMel if all other
criteria for possible beneﬁt are fulﬁlled. It is also possible that there
may be less beneﬁt for older patients, although this observation may
be by chance, and the test for interaction was not signiﬁcant.
BuMel was chosen as HDT based on international transplant
registry data16,18 and previous work by the French Society of Pe-
diatric Oncology.20 Concerns about interaction with radiotherapy,
including fatal toxicity, led to a protocol amendment after which
patients requiring large-volume or high-dose radiotherapy to critical
organs were excluded from randomization.23 There is little evidence
to deﬁne thresholds for concurrent use of radiotherapy and bu-
sulfan. Others have reported its use after whole-lung irradiation
without signiﬁcant toxicity.36 There are no data to support equiv-
alent efﬁcacy with treosulfan, which, although closely related to
busulfan, is less radiosensitizing.
We chose to compare BuMel against seven cycles of main-
tenance chemotherapy only. Given that the effect of HDT in this
series is seen in a reduction in the incidence of subsequent me-
tastases, which were often pulmonary, we cannot exclude that
whole-lung irradiation would have similar beneﬁts.37,38
Extrapolation of beneﬁt to other settings in ES is to be
cautioned against. A similar effect of BuMel on survival in pa-
tients presenting with pulmonary metastases was not observed
when bilateral pulmonary irradiation was added to conventional
Table 2. EFS and Overall Survival Analysis, Main Analysis on the Intention-To-Treat Population, and Sensitivity Analysis on the As-Treated Population
Outcome
Intention-To-Treat Analysis As-Treated Population*
VAI Arm (n = 118)
BuMel Arm
(n = 122) VAI Arm, n = 116 BuMel Arm (n = 93)
EFS
No. and type of events 60 45 60 33
Progression/relapse 56 37 56 27
Local progression or relapse 8 5 8 4
Without metastases 48 32 48 23
Distant metastases
With or without local
progression or relapse
Secondary malignancy 3 2 3 2
Death as ﬁrst reported event† 1 6 1 4
Treatment-related death 0 3‡ 0 2
Death from other cause 1 2§ 1 1
Death from unknown cause 0 1 0 1
3-year EFS since
randomization, % (95% CI)
56.7 (47.6 to 65.4) 69.0 (60.2 to 76.6) 56.0 (46.8 to 64.8) 71.7 (61.8 to 79.9)
8-year EFS since
randomization, % (95% CI)
47.1 (37.7 to 56.8) 60.7 (51.1 to 69.6) 46.3 (36.8 to 56.0) 62.8 (51.9 to 72.6)
HR of event (95% CI)k 1 0.64 (0.43 to 0.95)¶ 1 0.57 (0.37 to 0.88)
P .026# .010
Adjusted HR of event (95% CI)# 1 0.65 (0.44 to 0.96) 1 0.58 (0.38 to 0.89)
P .032 .012
Overall survival
No. and cause of deaths 53 37 53 28
Due to progression/relapse 48 31 48 24
Treatment-related death 0 3§ 0 2
Secondary malignancy 4 0 4 0
Other cause 1 2k 1 1
Unknown cause 1 1
3-y OS from randomization, %
(95% CI)
72.2 (63.3 to 79.6) 78.0 (69.6 to 84.5) 71.7 (62.8 to 79.2) 79.2 (69.8 to 86.3)
8-y OS from randomization, %
(95% CI)
55.6 (45.8 to 65.1) 64.5 (54.4 to 73.5) 55.0 (45.1 to 64.5) 65.4 (54.1 to 75.3%)
HR of death (95% CI)k 1 0.63 (0.41 to 0.95) 1 0.58 (0.37 to 0.92)
P .028 .019
Adjusted HR of death
(95% CI)#
1 0.64 (0.42 to 0.97) 1 0.59 (0.37 to 0.93)
P .035 .022
Abbreviations: BuMel, busulfan and melphalan; EFS, event-free survival; HR, hazard ratio; OS, overall survival; VAI, vincristine, dactinomycin, and ifosfamide.
*As-treated data set: excluding 31 patients (two in the VAI arm, 29 in the BuMel arm); 28 patients with a major treatment modiﬁcation (Data Supplement); three patients
with missing information about received treatment.
†The seven deaths as ﬁrst events are detailed in the Data Supplement.
‡Three treatment-related deaths were reported in the BuMel arm, but one occurred in a patient who did not receive BuMel (allocated to BuMel, but received two VAI
courses and no BuMel because of limited renal function; renal insufﬁciency and cardiac insufﬁciency, leading to death 3 months after randomization).
§Two deaths due to another cause were reported in the BuMel arm, but one occurred in a patient who did not receive BuMel because of patient choice.
║Hazard ratios with their 95% CIs and P values were estimated in Cox models including only the treatment effect as a covariable, with prior check of the proportional
hazards assumption by adding a time-interaction term and by using the Martingale-based residuals.30
¶The HR provided in the table for themain analysis of EFSwas corrected for the four previous interim analyses using the inverse normal method. Before this correction,
the HR was 0.64 (95% CI, 0.43 to 0.94; P = .023).
#Hazard ratios with their 95%CIs and P valueswere estimated in Coxmodels including the treatment effect and age in four categories (, 12, 12 to 18, 18 to 25,. 25) as
covariables.
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chemotherapy.37 Uncontrolled studies of HDT in patients with
recurrent ES describe some patients with far superior sur-
vival than would be expected from conventionally dosed che-
motherapy alone, but no randomized studies have been
conducted.39,40 It is possible that different induction regimens
may select different groups of patients for which the beneﬁts of
BuMel may also differ. Whether results similar to those reported
here are achievable with dose-compressed vincristine, doxoru-
bicin, cyclophosphamide/ifosfamide and etoposide is an open
question.2
As expected, more patients experienced severe toxicity in
the BuMel arm than in the VAI arm, mostly hematologic, di-
gestive, and hepatic. However, these types of toxicity were
transient and occurred only once after BuMel compared with
repetitive hematologic toxicity with VAI courses. Two patients
died as a result of BuMel toxicity, including one as a result of
interaction with radiotherapy. Recommendations for the use of
radiotherapy with BuMel as adopted during this study should
limit this risk. Long-term toxicity from this and similar cohorts
has yet to be reported.
These results are a further illustration of the value of in-
ternational collaboration in rare cancers such as ES. Although the
study was challenging to undertake, patients and their clinicians
can now beneﬁt from randomized evidence of the value of this
treatment. Although the beneﬁt was shown for a relatively small
subgroup, the reliable demonstration of EFS and OS improve-
ment indicates that BuMel may be considered as a standard of
care for patients with localized ES fulﬁlling the deﬁnition of
VAI 
More Toxic
BuMel
More Toxic
1010.1
Hematological toxicity
Infection
Liver toxicity
GI tract
General condition
Cardiac toxicity
Skin toxicity
Neurological toxicity
Renal toxicity
Lung toxicity
Haematuria/Bladder
VAI (n=116) BuMel (n=93)
100% 75% 75%50% 50%25% 25%0% 100%
All grades
Severe toxicity
All grades
Severe toxicity
Fig 3. Adverse events. The panel on the left is a butterﬂy plot showing the proportion of patients experiencing an adverse event, whatever the grade (gold for
busulfan andmelphalan [BuMel] and blue for the vincristine, dactinomycin, and ifosfamide [VAI] arm), and a severe adverse event (dark gold for BuMel and dark blue for
VAI arm) according to the randomization group. The panel on the right displays the relative risk of a severe adverse event in patients with BuMel relative to patients with
VAI, with 95% CIs for a 2 3 2 table. The acute toxicity related to chemotherapy was assessed after each course, using a list of 22 selected items from the National
Cancer Institute Common Toxicity Criteria version 2.0. A modiﬁed list of items was used to evaluate toxicity after radiotherapy, using Radiation Therapy Oncology
Group classiﬁcation for eight types of speciﬁc toxicities. A free text area was available to document other adverse reactions. The toxicity items were then pooled by
category: bladder toxicity, cardiac toxicity, GI toxicity, general deterioration, hematologic toxicity, infection, liver toxicity, lung toxicity, neurologic toxicity (including
mood alteration), renal toxicity, and skin toxicity. The respiratory tract toxicity (larynx, pharynx, salivary gland) reported after radiotherapy was pooled within the
category GI toxicity because of small numbers and because they were usually associated. Details are provided in the Data Supplement. For each adverse event type,
the analysis is based on the maximum grade observed over the whole maintenance treatment duration. A grade 4 hematologic toxicity and a grade $ 3 non-
hematologic toxicity were classiﬁed as severe toxicities. The categories of adverse event are ordered by decreasing value of the relative risk of severe toxicity. This
analysis was performed on the safety set (116 VAI patients and 93 BuMel patients), excluding patients who did not receive the treatment allocated by randomization,
similar to the as-treated population. The number of chemotherapy courses followed by toxicity over the whole maintenance treatment duration is detailed in the Data
Supplement.
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high-risk disease used in this trial and no contraindication to
BuMel.
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